MT Newswires
X4 Pharma Receives Positive EU Panel Opinion for WHIM Syndrome Drug
➖
AI Sentiment
Neutral
5/10
X4 Pharmaceuticals Inc. News
Latest updates and market news for XFOR
3 news
Feb 25 - Mar 3, 2026
Page 1
GlobeNewswire
X4 Pharmaceuticals Receives Positive Opinion from the EMA CHMP Recommending Approval of Mavorixafor in the EU for WHIM Syndrome
📈
AI Sentiment
Highly Positive
9/10
Share this news page